Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|October 14, 2021
SGS Invests in New E&L Laboratory in India
Author(s)Pharmaceutical Technology Editors
SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.
Advertisement
SGS announced on Oct. 12, 2021, that it is investing in a new extractables and leachables (E&L) testing laboratory in Navi Mumbai, India. The lab is set to open by the end of 2021 and will provide testing services for verifying product safety for pharmaceutical, biopharmaceutical, and medical device companies in Southeast Asia.
The new lab will be approximately 3000 ft.2 and will offer a broad spectrum of the latest E&L testing solutions, including:
- gas chromatography–mass spectrometry (GC–MS) and headspace–GC/MS for the analysis of semi-volatile and volatile components
- liquid chromatography with tandem mass spectrometry (LC–MSMS) for the quantitative analysis of trace leachable components
- high resolution LC–MSMS to generate data that supports identification of unknown components
- and inductively coupled plasma–MS to quantitate screening and identification of inorganics.
This laboratory in India will complement SGS's existing testing network. The company has three other E&L centers of excellence located in the United States, Germany, and China.
Source:
Advertisement
Related to this article
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
5